SUPPLEMENTAL MATERIAL

Table S1. Adjustment Variables used for the Cox Proportional Hazards Model by Score and Outcome.

	EQ-5D Index Score	EQ-5D VAS	PAQ
MACE	Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior MI, prior PCI, prior CABG, diabetes, statin use, tobacco use, prior major amputation, prior minor amputation, age, ABI, eGFR	Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior MI, prior PCI, diabetes, statin use, tobacco use, prior minor amputation, age, ABI, weight, eGFR	Rutherford score, sex, prior stroke, prior carotid revascularization, prior MI, prior PCI, prior CABG, diabetes, statin use, tobacco use, prior minor amputation, age, ABI, eGFR
MALE	Rutherford score, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes, ARB use, prior major or minor amputation, statin use, and ABI	Rutherford score, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes, ARB use, prior major or minor amputation, statin use, and ABI	Rutherford score, inclusion criteria, prior carotid revascularization, diabetes, prior major amputation, statin use, ABI, region and tobacco use
Lower extremity revascularization	Inclusion criteria, region, ABI, tobacco use, diabetes, prior clopidogrel use, prior aspirin use	Inclusion criteria, region, ABI, tobacco use, diabetes, prior clopidogrel use, prior aspirin use	Inclusion criteria, region, ABI, tobacco use, prior clopidogrel use, eGFR
Major Amputation	Rutherford score, inclusion criteria, prior CABG, diabetes, statin use, prior major amputation, prior minor amputation, ABI, weight	Rutherford score, inclusion criteria, prior carotid stenosis, prior carotid revascularization, diabetes, statin use, prior major amputation, prior minor amputation, ABI, weight	Rutherford score, prior carotid revascularization, diabetes, prior major amputation, prior minor amputation, ABI
Acute limb ischemia requiring hospitalization	Inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use	Inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use	Inclusion criteria, prior carotid revascularization, statin use, eGFR
	Change in EQ-5D Index Score	**Change in EQ-5D VAS**	**N/A**
MACE	Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior	Rutherford score, sex, inclusion criteria, region, prior stroke, prior carotid revascularization, prior	

	MI, prior PCI, prior CABG, diabetes, statin use, tobacco use, prior major amputation, prior minor amputation, age, ABI, eGFR	MI, prior PCI, diabetes, statin use, tobacco use, prior minor amputation, age, ABI, weight, eGFR	
MALE	Rutherford score, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes, ARB use, prior major or minor amputation, statin use, and ABI	Rutherford score, inclusion criteria, prior carotid revascularization, prior carotid stenosis, diabetes, ARB use, prior major or minor amputation, statin use, and ABI	
Lower extremity revascularization	Inclusion criteria, region, ABI, tobacco use, diabetes, prior clopidogrel use, prior aspirin use	Inclusion criteria, region, ABI, tobacco use, diabetes, prior clopidogrel use, prior aspirin use	
Major Amputation	Rutherford score, inclusion criteria, prior CABG, diabetes, statin use, prior major amputation, prior minor amputation, ABI, weight	Rutherford score, inclusion criteria, prior carotid stenosis, prior carotid revascularization, diabetes, statin use, prior major amputation, prior minor amputation, ABI, weight	
Acute limb ischemia requiring hospitalization	Inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use	Inclusion criteria, ABI, hypertension, prior carotid revascularization, ARB use	

ABI indicates ankle brachial index; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; EQ-5D, EuroQol-5D; MI, myocardial infarction; PCI, percutaneous coronary intervention; LER, lower extremity revascularization; MACE, major adverse cardiovascular event; MALE, major adverse limb event; PAQ, Peripheral Artery Questionnaire; VAS, visual analog scale

Table S2. Baseline Patient Characteristics by Tertile of EQ-5D Index Score.

Characteristic	0.0 to <0.69 (N=4,231)	0.69 to <0.79 (N=4,369)	0.79 to 1.0 (N=4,617)	P-value[α]
Age	66, 60-73	66, 60-72	66, 61-72	0.876
Female	33.1%	26.4%	24.9%	<.001
Weight, kg	78, 67-89	78, 68-89	75, 65-86	<.001
Inclusion Criteria				<.001
ABI/TBI	51.4%	47.7%	32.4%	
ABI value, Mean (SD)	0.62 (0.16)	0.62 (0.15)	0.65 (0.14)	<.001
TBI value, Mean (SD)	0.59 (0.27)	0.48 (0.16)	0.49 (0.17)	0.053
Prior lower extremity revascularization	48.6%	52.3%	67.6%	
ABI value, Mean (SD)	0.73 (0.23)	0.74 (0.22)	0.84 (0.21)	<.001
Limb Symptoms				<.001
Asymptomatic	8.1%	10.9%	36.3%	
Mild or Moderate Claudication	51.5%	59.8%	50.2%	
Severe Claudication	33.0%	25.8%	11.6%	
Pain while at Rest	4.5%	1.9%	1.1%	
Major or Minor Tissue Loss	3.0%	1.5%	0.9%	
Prior Major Amputation	3.9%	1.8%	1.1%	<.001
Prior PCI	14.8%	15.4%	15.7%	0.457
Prior CABG	10.6%	11.9%	11.1%	0.147
Medical History				

Characteristic	0.0 to <0.69 (N=4,231)	0.69 to <0.79 (N=4,369)	0.79 to 1.0 (N=4,617)	P-value[α]
Stroke	10.5%	7.1%	6.9%	<.001
Prior Myocardial Infarction	20.2%	17.8%	16.3%	<.001
Diabetes	40.9%	38.7%	34.5%	<.001
Hypertension	80.1%	79.5%	75.7%	<.001
Hyperlipidemia	73.6%	77.4%	76.2%	<.001
COPD	13.3%	11.9%	8.4%	<.001
Number of Vascular Beds				<.001
1	54.7%	55.8%	58.4%	
≥2	45.3%	44.2%	41.5%	
Tobacco Use				<.001
Current	29.6%	32.7%	31.0%	
Former	43.0%	47.1%	51.7%	
Medications Prior to Randomization				
Aspirin	61.2%	68.3%	71.0%	<.001
Clopidogrel	32.4%	29.9%	34.4%	<.001
Statin	69.7%	74.3%	75.4%	<.001
ACE Inhibitor	42.3%	43.4%	37.9%	<.001
ARB	24.1%	24.3%	26.0%	0.068

Characteristic	0.0 to <0.69 (N=4,231)	0.69 to <0.79 (N=4,369)	0.79 to 1.0 (N=4,617)	P-value$^\alpha$
Cilostazol	13.4%	14.4%	15.6%	0.013

ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe brachial index

$^\alpha$Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-square or Fisher's exact test.

Table S3. Baseline Characteristics by Tertile of EQ-5D VAS Score.

Characteristic	0 to 60 (N=4,683)	61 to 79 (N=3,866)	80 to 100 (N=4,984)	P-value[α]
Age	66, 60-73	66, 60-72	66, 61-72	0.239
Female	29.3%	26.0%	29.2%	<.001
Weight, kg	77, 66-89	78, 68-89	76, 66-87	<.001
Inclusion Criteria				<.001
ABI/TBI	48.2%	46.2%	37.9%	
ABI value, Mean (SD)	0.61 (0.17)	0.63 (0.14)	0.65 (0.14)	<.001
TBI value, Mean (SD)	0.50 (0.19)	0.56 (0.29)	0.51 (0.16)	0.324
Prior lower extremity revascularization	51.8%	53.8%	62.1%	
ABI value, Mean (SD)	0.73 (0.24)	0.77 (0.23)	0.81 (0.22)	<.001
Limb Symptoms				<.001
Asymptomatic	10.8%	16.1%	27.6%	
Mild or Moderate Claudication	49.6%	56.7%	54.0%	
Severe Claudication	31.9%	24.0%	15.2%	
Pain while at Rest	4.8%	1.5%	1.8%	
Major or Minor Tissue Loss	2.8%	1.7%	1.2%	
Prior Major Amputation	3.2%	2.0%	2.2%	<.001
Prior Minor Amputation	5.4%	4.4%	3.4%	<.001
Prior PCI	15.8%	14.6%	15.4%	0.302
Prior CABG	11.6%	10.7%	11.0%	0.374

Characteristic	0 to 60 (N=4,683)	61 to 79 (N=3,866)	80 to 100 (N=4,984)	P-value$^\alpha$
Medical History				
Stroke	10.8%	7.4%	6.3%	<.001
Myocardial Infarction	19.8%	17.9%	16.6%	<.001
Diabetes	40.2%	38.5%	36.2%	<.001
Hypertension	79.3%	79.0%	76.7%	0.004
Hyperlipidemia	73.6%	75.7%	77.5%	<.001
COPD	13.6%	11.1%	9.0%	<.001
Number of Vascular Beds				<.001
1	53.3%	56.9%	59.0%	
$\geq$2	46.7%	43.2%	41%	
Tobacco Use				<.001
Current	31.2%	30.8%	30.9%	
Former	42.7%	48.3%	50.8%	
Medications Prior to Randomization				
Aspirin	64.2%	65.1%	70.2%	<.001
Clopidogrel	32.8%	31.8%	32.2%	0.599
Statin	70.4%	73.3%	75.4%	<.001
Ace Inhibitor	42.3%	41.4%	39.4%	0.011
ARB	23.7%	25.1%	25.6%	0.073

Characteristic	0 to 60 (N=4,683)	61 to 79 (N=3,866)	80 to 100 (N=4,984)	P-value$^\alpha$
Cilostazol	12.9%	14.5%	16.3%	<.001

ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe brachial index

$^\alpha$Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-square or Fisher's exact test.

Table S4. Baseline Characteristics by Tertile of PAQ Score.

Characteristic	0 to 49 (N=1,479)	50 to 75 (N=1,473)	76 to 108 (N=1,479)	P-value[α]
Age	66, 60-73	67, 62-73	68, 61-73	<.001
Female	34.8%	31.0%	28.9%	0.003
Weight, kg	82, 70-95	80, 69-92	79, 68-90	<.001
Inclusion Criteria				<.001
ABI/TBI	31.3%	29.7%	15.6%	
ABI value, Mean (SD)	0.64 (0.17)	0.66 (0.15)	0.67 (0.16)	0.012
TBI value, Mean (SD)	0.46 (0.15)	0.37 (0.15)	0.37 (0.20)	0.388
Prior lower extremity revascularization	68.7%	70.3%	84.4%	
ABI value, Mean (SD)	0.77 (0.22)	0.81 (0.21)	0.88 (0.20)	<.001
Limb Symptoms				<.001
Asymptomatic	5.5%	14.7%	49.6%	
Mild or Moderate Claudication	50.2%	63.7%	44.3%	
Severe Claudication	37.3%	20.0%	4.4%	
Pain while at Rest	5.3%	1.0%	1.2%	
Major or Minor Tissue Loss	1.6%	0.4%	0.6%	
Prior Major Amputation	2.6%	1.2%	1.3%	0.002
Prior Minor Amputation	3.8%	2.7%	2.1%	0.020
Prior PCI	27.5%	25.9%	23.7%	0.061
Prior CABG	20.6%	20.0%	15.4%	<.001

Characteristic	0 to 49 (N=1,479)	50 to 75 (N=1,473)	76 to 108 (N=1,479)	P-value[α]
Medical History				
Stroke	7.6%	6.7%	5.5%	0.070
Prior Myocardial Infarction	23.9%	23.2%	19.3%	0.006
Diabetes	45.2%	39.3%	31.8%	<.001
Hypertension	85.2%	83.7%	80.0%	<.001
Hyperlipidemia	89.9%	88.5%	87.5%	0.110
COPD	24.7%	17.7%	10.7%	<.001
Number of Vascular Beds				<.001
1	42.6%	43.3%	49.5%	
≥2	57.4%	56.7%	50.5%	
Tobacco Use				0.030
Current	37.9%	33.6%	32.8%	
Former	50.5%	55.1%	55.0%	
Medications Prior to Randomization				
Aspirin	73.8%	78.3%	81.9%	<.001
Clopidogrel	43.7%	38.5%	42.6%	0.011
Statin	83.4%	83.4%	85.9%	0.092
Ace Inhibitor	45.0%	43.0%	43.0%	0.434
ARB	25.3%	26.1%	23.9%	0.380

Characteristic	0 to 49 (N=1,479)	50 to 75 (N=1,473)	76 to 108 (N=1,479)	P-value$^\alpha$
Cilostazol	14.3%	13.8%	9.5%	<.001

ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; COPD; chronic obstructive pulmonary disease; kg, kilogram; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe brachial index

$^\alpha$Continuous variables were compared using an ANOVA or Kruskal Wallis test and categorial variables were compared using chi-square or Fisher's exact test.

Table S5. Trends in Health status Measures over the Trial Follow-up.

Measure	Baseline	Month 12	Month 24
EQ-5D Index Score			
N	9979	9979	9979
Mean (SD)	0.73 (0.19)	0.76 (0.19)	0.76 (0.19)
Median (IQR)	0.73, 0.66-0.85	0.73, 0.69-0.85	0.73, 0.69-0.85
EQ-5D Visual Analog Scale			
N	10443	10443	10443
Mean (SD)	68.7 (19.5)	70.4 (18.7)	70.9 (18.9)
Median (IQR)	70, 60-80	72, 60-80	75, 60-80
PAQ			
N	3225	3225	3225
Mean (SD)	62.97 (24.2)	66.81 (24.3)	67.57 (24.8)
Median (IQR)	65, 44-83	69, 50-87	71, 50-89

EQ-5D indicates EuroQol 5-Dimensions; IQR, interquartile range; PAQ, Peripheral Artery Questionnaire; SD, standard deviation

Table S6. Number of Clinical Events by Tertile of Health Status Instrument.

Event Rates by Tertile of Health Status Instrument Score			
Clinical Outcome	**Tertile 1*** **Rate (Events)**	**Tertile 2** **Rate (Events)**	**Tertile 3** **Rate (Events)**
EQ-5D (N=13,217)			
MACE	5.32 (525)	4.55 (480)	3.58 (405)
MALE	1.49 (148)	1.13 (121)	0.85 (98)
ALI Requiring Hospitalization	0.82 (82)	0.60 (65)	0.64 (74)
Major Amputation	0.86 (86)	0.63 (68)	0.33 (38)
LER	5.61 (527)	5.84 (588)	4.89 (531)
VAS (N=13,533)			
MACE	5.72 (624)	4.20 (392)	3.65 (445)
MALE	1.59 (176)	1.24 (117)	0.81 (101)
ALI Requiring Hospitalization	0.87 (97)	0.70 (67)	0.51 (64)
Major Amputation	0.93 (104)	0.66 (63)	0.38 (48)
LER	6.16 (638)	5.25 (470)	4.99 (583)
PAQ (N=4,431)			
MACE	7.24 (249)	5.20 (186)	3.48 (129)
MALE	1.51 (54)	0.87 (32)	0.83 (31)
ALI Requiring Hospitalization	0.86 (31)	0.57 (21)	0.66 (25)
Major Amputation	0.75 (27)	0.48 (18)	0.24 (9)

Event Rates by Tertile of Health Status Instrument Score			
Clinical Outcome	Tertile 1* Rate (Events)	Tertile 2 Rate (Events)	Tertile 3 Rate (Events)
LER	12.8 (392)	9.22 (304)	6.82 (236)

ALI indicates acute limb ischemia; EQ-5D, EuroQol-5D; HR, hazards ratio; LER, lower extremity revascularization; MACE, major adverse cardiovascular event; MALE, major adverse limb event; PAQ, peripheral artery questionnaire; VAS, visual analog scale

Tertile 1 is defined as 0-<0.69 for EQ-5D Index Score, 0.69-<0.79 for Tertile 2, and from 0.79-1.0 for Tertile 3. Tertile 1 is defined as 0-60 for VAS, 61-79 for Tertile 2, and 80-100 for Tertile 3. Tertile 1 is defined as 0-49 for PAQ, 50-75 for Tertile 2, and 76-108 for Tertile 3.

Table S7. Baseline Characteristics of Patients Included vs. Excluded from Change Analysis.

Characteristic	Excluded from Analysis (N=1669)	Included in Analysis (N=11913)
Age	68, 62-75	66, 60-72
Female	29.8%	28.1%
Weight, kg	76, 65-87	77, 67-88
Inclusion Criteria		
ABI/TBI	43.9%	43.8%
Prior lower extremity revascularization	56.1%	56.2%
Limb Symptoms		
Asymptomatic	16.1%	18.9%
Mild or Moderate Claudication	47.1%	54.1%
Severe Claudication	28.4%	22.9%
Pain while at Rest	4.6%	2.5%
Minor Tissue Loss	2.9%	1.3%
Major Tissue Loss	1.0%	0.3%
Prior Major Amputation	3.5%	2.3%
Prior Minor Amputation	6.6%	4.1%
Prior PCI	16.7%	15.1%
Prior CABG	13.5%	10.8%
Medical History		
Stroke	9.1%	960 (8.1%

Characteristic	Excluded from Analysis (N=1669)	Included in Analysis (N=11913)
CAD	31.9%	28.3%
MI	20.6%	17.8%
Diabetes	41.5%	37.8%
Hypertension	79.2%	78.1%
Hyperlipidemia	74.8%	75.8%
COPD	13.5%	10.8%
Liver Disease	2.0%	2.0%
Number of Vascular Beds		
1	53.9%	56.8%
2	34.3%	33.5%
3	11.7%	9.8%
Tobacco Use		
Current	29.9%	31.1%
Former	46.3%	47.4%
Medications Prior to Randomization		
Aspirin	66.2%	66.7%
Clopidogrel	33.6%	32.1%
Statin	69.6%	73.6%
ACE Inhibitor	41.3%	41.0%
ARB	24.0%	24.9%

Characteristic	Excluded from Analysis (N=1669)	Included in Analysis (N=11913)
Cilostazol	16.4%	14.3%

ABI indicates ankle brachial index; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD; chronic obstructive pulmonary disease; kg, kilogram; MI; myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; TBI, toe brachial index

Figure S1. Boxplot of Change in Health Status Instrument Scores at the 12 Month and 24 Month Trial Follow-up (1a- EQ-5D, 1b- EQ VAS, 1c- PAQ).

The boxplots illustrate the change in the various health status instruments scores at baseline, 12-month follow-up and at 24 months follow-up. Each boxplot illustrates the minimum and maximum scores, the median score, and the interquartile range.